HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.

AbstractOBJECTIVE:
We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC). Because the optimum dose of this combination was unknown, we used a phase I/II design.
METHODS:
In the phase I cohort, patients received 110 mg/m2 TMTX intravenously weekly x6 and CAP starting at 750 mg/m2 orally twice daily from days 2 to 15 and 23 to 36 (one cycle). Cycles were repeated every 8 weeks. The phase II doses were 110 mg/m2 TMTX and 1000 mg/m2 CAP orally twice daily.
RESULTS:
Thirty-two patients were entered. All patients had prior 5-fluorouracil therapy and 94% had prior exposure to irinotecan. Grade 3/4 toxicities included abdominal pain in 4 patients (12.5%) and vomiting in 3 patients (9.4%). Twenty-seven patients were evaluable for response: one patient each had a complete response and a partial response for an overall response rate of 7.4%. The median time to progression was 3.3 months (95% confidence interval [CI], 1.6-3.7 months) and the median overall survival was 5.9 months (95% CI, 5.2-10.2 months).
CONCLUSIONS:
The combination of TMTX and CAP is well tolerated. However, recent studies have shown more active regimens in the second- and third-line metastatic setting.
AuthorsKhalid Matin, Samuel A Jacobs, Thomas Richards, Michael K Wong, Martin Earle, Terry Evans, Monica Troetschel, William Ferri, David Friedland, Richard Pinkerton, Robert Volkin, Samuel Wieand, Ramesh K Ramanathan
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 28 Issue 5 Pg. 439-44 (Oct 2005) ISSN: 1537-453X [Electronic] United States
PMID16199980 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil
  • Trimetrexate
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Capecitabine
  • Colorectal Neoplasms (drug therapy, pathology)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Female
  • Fluorouracil (analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Trimetrexate (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: